Chondroitin sulfate proteoglycans: Key modulators in the developing and pathologic central nervous system
Chondroitin Sulfate Proteoglycans (CSPGs) are a major component of the extracellular matrix in the central nervous system (CNS) and play critical role in the development and pathophysiology of the brain and spinal cord. Developmentally, CSPGs provide guidance cues for growth cones and contribute to...
Gespeichert in:
Veröffentlicht in: | Experimental neurology 2015-07, Vol.269, p.169-187 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 187 |
---|---|
container_issue | |
container_start_page | 169 |
container_title | Experimental neurology |
container_volume | 269 |
creator | Dyck, Scott M. Karimi-Abdolrezaee, Soheila |
description | Chondroitin Sulfate Proteoglycans (CSPGs) are a major component of the extracellular matrix in the central nervous system (CNS) and play critical role in the development and pathophysiology of the brain and spinal cord. Developmentally, CSPGs provide guidance cues for growth cones and contribute to the formation of neuronal boundaries in the developing CNS. Their presence in perineuronal nets plays a crucial role in the maturation of synapses and closure of critical periods by limiting synaptic plasticity. Following injury to the CNS, CSPGs are dramatically upregulated by reactive glia which form a glial scar around the lesion site. Increased level of CSPGs is a hallmark of all CNS injuries and has been shown to limit axonal plasticity, regeneration, remyelination, and conduction after injury. Additionally, CSPGs create a non-permissive milieu for cell replacement activities by limiting cell migration, survival and differentiation. Mounting evidence is currently shedding light on the potential benefits of manipulating CSPGs in combination with other therapeutic strategies to promote spinal cord repair and regeneration. Moreover, the recent discovery of multiple receptors for CSPGs provides new therapeutic targets for targeted interventions in blocking the inhibitory properties of CSPGs following injury. Here, we will provide an in depth discussion on the impact of CSPGs in normal and pathological CNS. We will also review the recent preclinical therapies that have been developed to target CSPGs in the injured CNS.
•CSPGs have a critical role in the development, maintenance and pathology of the CNS.•Following injury to the CNS, CSPGs expression is markedly upregulated.•CSPGs limit cell replacement, axonal sprouting, regeneration and remyelination.•Inhibiting CSPGs function is a realistic therapeutic target for repair following SCI.•Recent discovery of four CSPGs receptors provide novel therapeutic targets for SCI. |
doi_str_mv | 10.1016/j.expneurol.2015.04.006 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1698390244</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S001448861500120X</els_id><sourcerecordid>1698390244</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-8ee3d2538d232c1d27687770afcd247495db1169eb33f84215a11c4fbe91c8b73</originalsourceid><addsrcrecordid>eNqFkEuP0zAURi0EYsrAXwAv2ST4lThhN6p4iZHYwNpy7JvWlWMH26nov8ejDrNldXWl893HQegdJS0ltP9wauHPGmBL0beM0K4loiWkf4Z2lIykYYKT52hHCBWNGIb-Br3K-UQIGQWTL9EN68badN0Ouf0xBpuiKy7gvPlZF8BrigXiwV-MDvkj_g4XvES7eV1iyriC5QjYwhl8XF04YB0sXnU5Rh8PzmADoSTtcYB0jlvG-ZILLK_Ri1n7DG8e6y369fnTz_3X5v7Hl2_7u_vGCC5LMwBwyzo-WMaZoZbJfpBSEj0by4QUY2cnSvsRJs7nQTDaaUqNmCcYqRkmyW_R--vc-sXvDXJRi8sGvNcB6jWqZgc-EiZEReUVNSnmnGBWa3KLThdFiXrwrE7qybN68KyIUNVzTb59XLJNC9in3D-xFbi7AlBfPTtIKhsHwYB1CUxRNrr_LvkLpsCVfg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1698390244</pqid></control><display><type>article</type><title>Chondroitin sulfate proteoglycans: Key modulators in the developing and pathologic central nervous system</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Dyck, Scott M. ; Karimi-Abdolrezaee, Soheila</creator><creatorcontrib>Dyck, Scott M. ; Karimi-Abdolrezaee, Soheila</creatorcontrib><description>Chondroitin Sulfate Proteoglycans (CSPGs) are a major component of the extracellular matrix in the central nervous system (CNS) and play critical role in the development and pathophysiology of the brain and spinal cord. Developmentally, CSPGs provide guidance cues for growth cones and contribute to the formation of neuronal boundaries in the developing CNS. Their presence in perineuronal nets plays a crucial role in the maturation of synapses and closure of critical periods by limiting synaptic plasticity. Following injury to the CNS, CSPGs are dramatically upregulated by reactive glia which form a glial scar around the lesion site. Increased level of CSPGs is a hallmark of all CNS injuries and has been shown to limit axonal plasticity, regeneration, remyelination, and conduction after injury. Additionally, CSPGs create a non-permissive milieu for cell replacement activities by limiting cell migration, survival and differentiation. Mounting evidence is currently shedding light on the potential benefits of manipulating CSPGs in combination with other therapeutic strategies to promote spinal cord repair and regeneration. Moreover, the recent discovery of multiple receptors for CSPGs provides new therapeutic targets for targeted interventions in blocking the inhibitory properties of CSPGs following injury. Here, we will provide an in depth discussion on the impact of CSPGs in normal and pathological CNS. We will also review the recent preclinical therapies that have been developed to target CSPGs in the injured CNS.
•CSPGs have a critical role in the development, maintenance and pathology of the CNS.•Following injury to the CNS, CSPGs expression is markedly upregulated.•CSPGs limit cell replacement, axonal sprouting, regeneration and remyelination.•Inhibiting CSPGs function is a realistic therapeutic target for repair following SCI.•Recent discovery of four CSPGs receptors provide novel therapeutic targets for SCI.</description><identifier>ISSN: 0014-4886</identifier><identifier>EISSN: 1090-2430</identifier><identifier>DOI: 10.1016/j.expneurol.2015.04.006</identifier><identifier>PMID: 25900055</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Axonal regeneration ; Brain Injuries - drug therapy ; Central ; Central Nervous System - drug effects ; Central Nervous System - metabolism ; Chondroitin sulfate proteoglycans ; Chondroitin Sulfate Proteoglycans - metabolism ; Chondroitin Sulfate Proteoglycans - pharmacology ; Development ; Extracellular matrix ; Glial scar ; Humans ; Intacellular mechanisms ; LAR ; Multiple sclerosis ; Nerve Regeneration - drug effects ; Nerve Regeneration - physiology ; Nervous system ; Neuronal Plasticity - drug effects ; Plasticity ; PTPσ ; Spinal Cord Injuries - drug therapy ; Spinal cord injury</subject><ispartof>Experimental neurology, 2015-07, Vol.269, p.169-187</ispartof><rights>2015 Elsevier Inc.</rights><rights>Copyright © 2015 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c437t-8ee3d2538d232c1d27687770afcd247495db1169eb33f84215a11c4fbe91c8b73</citedby><cites>FETCH-LOGICAL-c437t-8ee3d2538d232c1d27687770afcd247495db1169eb33f84215a11c4fbe91c8b73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.expneurol.2015.04.006$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25900055$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dyck, Scott M.</creatorcontrib><creatorcontrib>Karimi-Abdolrezaee, Soheila</creatorcontrib><title>Chondroitin sulfate proteoglycans: Key modulators in the developing and pathologic central nervous system</title><title>Experimental neurology</title><addtitle>Exp Neurol</addtitle><description>Chondroitin Sulfate Proteoglycans (CSPGs) are a major component of the extracellular matrix in the central nervous system (CNS) and play critical role in the development and pathophysiology of the brain and spinal cord. Developmentally, CSPGs provide guidance cues for growth cones and contribute to the formation of neuronal boundaries in the developing CNS. Their presence in perineuronal nets plays a crucial role in the maturation of synapses and closure of critical periods by limiting synaptic plasticity. Following injury to the CNS, CSPGs are dramatically upregulated by reactive glia which form a glial scar around the lesion site. Increased level of CSPGs is a hallmark of all CNS injuries and has been shown to limit axonal plasticity, regeneration, remyelination, and conduction after injury. Additionally, CSPGs create a non-permissive milieu for cell replacement activities by limiting cell migration, survival and differentiation. Mounting evidence is currently shedding light on the potential benefits of manipulating CSPGs in combination with other therapeutic strategies to promote spinal cord repair and regeneration. Moreover, the recent discovery of multiple receptors for CSPGs provides new therapeutic targets for targeted interventions in blocking the inhibitory properties of CSPGs following injury. Here, we will provide an in depth discussion on the impact of CSPGs in normal and pathological CNS. We will also review the recent preclinical therapies that have been developed to target CSPGs in the injured CNS.
•CSPGs have a critical role in the development, maintenance and pathology of the CNS.•Following injury to the CNS, CSPGs expression is markedly upregulated.•CSPGs limit cell replacement, axonal sprouting, regeneration and remyelination.•Inhibiting CSPGs function is a realistic therapeutic target for repair following SCI.•Recent discovery of four CSPGs receptors provide novel therapeutic targets for SCI.</description><subject>Animals</subject><subject>Axonal regeneration</subject><subject>Brain Injuries - drug therapy</subject><subject>Central</subject><subject>Central Nervous System - drug effects</subject><subject>Central Nervous System - metabolism</subject><subject>Chondroitin sulfate proteoglycans</subject><subject>Chondroitin Sulfate Proteoglycans - metabolism</subject><subject>Chondroitin Sulfate Proteoglycans - pharmacology</subject><subject>Development</subject><subject>Extracellular matrix</subject><subject>Glial scar</subject><subject>Humans</subject><subject>Intacellular mechanisms</subject><subject>LAR</subject><subject>Multiple sclerosis</subject><subject>Nerve Regeneration - drug effects</subject><subject>Nerve Regeneration - physiology</subject><subject>Nervous system</subject><subject>Neuronal Plasticity - drug effects</subject><subject>Plasticity</subject><subject>PTPσ</subject><subject>Spinal Cord Injuries - drug therapy</subject><subject>Spinal cord injury</subject><issn>0014-4886</issn><issn>1090-2430</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEuP0zAURi0EYsrAXwAv2ST4lThhN6p4iZHYwNpy7JvWlWMH26nov8ejDrNldXWl893HQegdJS0ltP9wauHPGmBL0beM0K4loiWkf4Z2lIykYYKT52hHCBWNGIb-Br3K-UQIGQWTL9EN68badN0Ouf0xBpuiKy7gvPlZF8BrigXiwV-MDvkj_g4XvES7eV1iyriC5QjYwhl8XF04YB0sXnU5Rh8PzmADoSTtcYB0jlvG-ZILLK_Ri1n7DG8e6y369fnTz_3X5v7Hl2_7u_vGCC5LMwBwyzo-WMaZoZbJfpBSEj0by4QUY2cnSvsRJs7nQTDaaUqNmCcYqRkmyW_R--vc-sXvDXJRi8sGvNcB6jWqZgc-EiZEReUVNSnmnGBWa3KLThdFiXrwrE7qybN68KyIUNVzTb59XLJNC9in3D-xFbi7AlBfPTtIKhsHwYB1CUxRNrr_LvkLpsCVfg</recordid><startdate>201507</startdate><enddate>201507</enddate><creator>Dyck, Scott M.</creator><creator>Karimi-Abdolrezaee, Soheila</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201507</creationdate><title>Chondroitin sulfate proteoglycans: Key modulators in the developing and pathologic central nervous system</title><author>Dyck, Scott M. ; Karimi-Abdolrezaee, Soheila</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-8ee3d2538d232c1d27687770afcd247495db1169eb33f84215a11c4fbe91c8b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Axonal regeneration</topic><topic>Brain Injuries - drug therapy</topic><topic>Central</topic><topic>Central Nervous System - drug effects</topic><topic>Central Nervous System - metabolism</topic><topic>Chondroitin sulfate proteoglycans</topic><topic>Chondroitin Sulfate Proteoglycans - metabolism</topic><topic>Chondroitin Sulfate Proteoglycans - pharmacology</topic><topic>Development</topic><topic>Extracellular matrix</topic><topic>Glial scar</topic><topic>Humans</topic><topic>Intacellular mechanisms</topic><topic>LAR</topic><topic>Multiple sclerosis</topic><topic>Nerve Regeneration - drug effects</topic><topic>Nerve Regeneration - physiology</topic><topic>Nervous system</topic><topic>Neuronal Plasticity - drug effects</topic><topic>Plasticity</topic><topic>PTPσ</topic><topic>Spinal Cord Injuries - drug therapy</topic><topic>Spinal cord injury</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dyck, Scott M.</creatorcontrib><creatorcontrib>Karimi-Abdolrezaee, Soheila</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Experimental neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dyck, Scott M.</au><au>Karimi-Abdolrezaee, Soheila</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chondroitin sulfate proteoglycans: Key modulators in the developing and pathologic central nervous system</atitle><jtitle>Experimental neurology</jtitle><addtitle>Exp Neurol</addtitle><date>2015-07</date><risdate>2015</risdate><volume>269</volume><spage>169</spage><epage>187</epage><pages>169-187</pages><issn>0014-4886</issn><eissn>1090-2430</eissn><abstract>Chondroitin Sulfate Proteoglycans (CSPGs) are a major component of the extracellular matrix in the central nervous system (CNS) and play critical role in the development and pathophysiology of the brain and spinal cord. Developmentally, CSPGs provide guidance cues for growth cones and contribute to the formation of neuronal boundaries in the developing CNS. Their presence in perineuronal nets plays a crucial role in the maturation of synapses and closure of critical periods by limiting synaptic plasticity. Following injury to the CNS, CSPGs are dramatically upregulated by reactive glia which form a glial scar around the lesion site. Increased level of CSPGs is a hallmark of all CNS injuries and has been shown to limit axonal plasticity, regeneration, remyelination, and conduction after injury. Additionally, CSPGs create a non-permissive milieu for cell replacement activities by limiting cell migration, survival and differentiation. Mounting evidence is currently shedding light on the potential benefits of manipulating CSPGs in combination with other therapeutic strategies to promote spinal cord repair and regeneration. Moreover, the recent discovery of multiple receptors for CSPGs provides new therapeutic targets for targeted interventions in blocking the inhibitory properties of CSPGs following injury. Here, we will provide an in depth discussion on the impact of CSPGs in normal and pathological CNS. We will also review the recent preclinical therapies that have been developed to target CSPGs in the injured CNS.
•CSPGs have a critical role in the development, maintenance and pathology of the CNS.•Following injury to the CNS, CSPGs expression is markedly upregulated.•CSPGs limit cell replacement, axonal sprouting, regeneration and remyelination.•Inhibiting CSPGs function is a realistic therapeutic target for repair following SCI.•Recent discovery of four CSPGs receptors provide novel therapeutic targets for SCI.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25900055</pmid><doi>10.1016/j.expneurol.2015.04.006</doi><tpages>19</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-4886 |
ispartof | Experimental neurology, 2015-07, Vol.269, p.169-187 |
issn | 0014-4886 1090-2430 |
language | eng |
recordid | cdi_proquest_miscellaneous_1698390244 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Animals Axonal regeneration Brain Injuries - drug therapy Central Central Nervous System - drug effects Central Nervous System - metabolism Chondroitin sulfate proteoglycans Chondroitin Sulfate Proteoglycans - metabolism Chondroitin Sulfate Proteoglycans - pharmacology Development Extracellular matrix Glial scar Humans Intacellular mechanisms LAR Multiple sclerosis Nerve Regeneration - drug effects Nerve Regeneration - physiology Nervous system Neuronal Plasticity - drug effects Plasticity PTPσ Spinal Cord Injuries - drug therapy Spinal cord injury |
title | Chondroitin sulfate proteoglycans: Key modulators in the developing and pathologic central nervous system |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T23%3A03%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chondroitin%20sulfate%20proteoglycans:%20Key%20modulators%20in%20the%20developing%20and%20pathologic%20central%20nervous%20system&rft.jtitle=Experimental%20neurology&rft.au=Dyck,%20Scott%20M.&rft.date=2015-07&rft.volume=269&rft.spage=169&rft.epage=187&rft.pages=169-187&rft.issn=0014-4886&rft.eissn=1090-2430&rft_id=info:doi/10.1016/j.expneurol.2015.04.006&rft_dat=%3Cproquest_cross%3E1698390244%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1698390244&rft_id=info:pmid/25900055&rft_els_id=S001448861500120X&rfr_iscdi=true |